Mentions
Extended reach
Total likes
Video views
AI synopsis
Participants highlight the trial’s demonstration that rivaroxaban monotherapy is noninferior in efficacy while being superior in safety, using phrases like 'confidence to use a DOAC alone' and 'practice changing'. The tone is professional and analytical, supported by references to trial details, webinars, and clinical implications, illustrating strong consensus and interest in adopting these findings in practice.
Most discussions emphasize the positive findings of the trial, supporting the idea that rivaroxaban monotherapy is effective and safer, indicating strong consensus.
The broad participation, with references to multiple analyses, webinars, and expert opinions, reflects high engagement and curiosity among professionals.
Many posts reference detailed trial outcomes, safety benefits, and clinical implications, showing deep engagement and analysis.
The discussions focus on how this trial could influence clinical practice, such as reducing bleeding risks and simplifying therapy, demonstrating high real-world impact.
Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語っていただきます！オンデマンドなしなのでご興味がある方は是非ご視聴ください
@BaylorCardio #AFIRE trial: https://t.co/ZqsYpUIvSQ Summary of recent #ACCExpertConsensus below #AtrialFibrillation #StableCAD #Cardiotwitter #EPeeps @kerrigjl @cardiofrizz @melchami99 @DrAnkitKPatel @AnkurKalraMD @BagaiJayant @mobitz @evhaddad @Amyers235 @TTelila @KevinShahMD https://t.co/a1PtBRMQrE
The Afire study of 2236 AF patients >1 yr post PCI/CABG/angioCAD NOAC was non-inferior to combo NOAC/anti-platelet therapy for efficacy but SUPERIOR for bleeding DOI: 10.1056/NEJMoa1904143 this sub-analysis shows this is irrespective of the risks of stroke/bleeding @PCCS_UK https://t.co/UzRK6ipXD5
@Umair2017 @KemalogluOz @mirvatalasnag @KardiologieHH @ZainabDakhil2 @alaide_chief @mmamas1973 @gbiondizoccai @FrancescoPaneni @iamritu Only OAC-- I would consider this situation to be similar to AF and follow the lessons from the AFIRE trial. It's not perfect evidence but it feels right to me. https://t.co/J3Sw8r3sxG
Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/A008Lu6LAU https://t.co/RlixMkw8Jh
This week, John Mandrola MD discusses key findings from the Danish Cardiovascular Screening Trial. The trial, involving over 46,000 men aged 65-74, showed no significant reduction in mortality but indicated lower rates…
Prof. Bikdeli and Prof. Didier discuss the HIPRO study on extended treatment of provoked venous thromboembolism, presented at the 2025 European Society of Cardiology meeting. The study compares rivaroxaban monotherapy…
Prof Romain Didier and Prof Behnood Bikdeli discuss the AQUATIC study on antiplatelet drugs in patients with chronic coronary syndrome receiving oral anticoagulation, highlighting recent findings on therapy optimization…
AFIRE試験と類似方向の結果 https://t.co/iwfEKl94v9
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | New England Journal of Medicine https://t.co/bdguc7jnty
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | New England Journal of Medicine https://t.co/sQEMcmUCYA
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
RT @YuyaMatsue: 直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語…
直近で申し訳ないのですが、明日の夜7時より東北大学安田教授に日本オリジナル＋ESCでのHot Lineで発表＋NEJMに同時掲載という偉業を成し遂げた、AFIRE研究https://t.co/MhUf1ISgfqに関して文字通りNEJMへの道を語っていただきます！オンデマンドなしなのでご興味がある方は是非ご視聴ください
RT @djc795: @Umair2017 @KemalogluOz @mirvatalasnag @KardiologieHH @ZainabDakhil2 @alaide_chief @mmamas1973 @gbiondizoccai @FrancescoPaneni…
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/jn4759sjDi
@Umair2017 @KemalogluOz @mirvatalasnag @KardiologieHH @ZainabDakhil2 @alaide_chief @mmamas1973 @gbiondizoccai @FrancescoPaneni @iamritu Only OAC-- I would consider this situation to be similar to AF and follow the lessons from the AFIRE trial. It's not perfect evidence but it feels right to me. https://t.co/J3Sw8r3sxG
@bmorecardiology I see it all the time and frequently take stable CAD/AF patients on double therapy off their anti-platelets assuming they remain on OAC. See AFIRE trial (rivaroxaban vs. rivaroxaban + anti-platelet, stopped early due to increased mortality in combo group) https://t.co/aX8Pgp6tBZ
RT @HanchateShivani: 6/ AFIRE trial
RT @HanchateShivani: 6/ AFIRE trial
6/ AFIRE trial
@KertViele @DrToddLee @bordistef @drjohnm @kaulcsmc @bogdienache Interestingly the NEJM was very funny with the AFIRE trial when they met non inferiority, then were superior but the journal would not let them claim that .. https://t.co/uuwQmIFoeC
RT @BaoGTran: @richardbogle The bulk of the evidence say that once patient is stable, bleeding risk of combination DOAC and ASA outweighs b…
@richardbogle The bulk of the evidence say that once patient is stable, bleeding risk of combination DOAC and ASA outweighs benefits compared to DOAC alone in this scenario. https://t.co/5jncuLNcYk
DOAC併用のときに抗血小板薬中止するかどうか S33 #医療薬学会2022 https://t.co/EN3qdNq5V4
Today, I presented Journal Club reviewing the AFIRE trial (https://t.co/K0YN31eshX) @UAZHeart with Dr. Craig Hoover. I always analyze trials using the Race Analogy as taught by my mentor @ChrisDJacksonMD! It's the only way to make therapy trial results make sense to me. 1/2
RT @TomohiroFujisa2: AFIRE trial. 2019 NEJM. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.c…
AFIRE trial. 2019 NEJM. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/BGjgETSZVv
RT @Bibleblack3: @May_Roma 例えば最近の文献で見ると、虚血性心疾患を合併した心房細動でも3年の観察期間で起きるイベントはせいぜい15%程度です。 医療は本当に進歩しています。 https://t.co/4i5CA35hZA
RT @Bibleblack3: @May_Roma 例えば最近の文献で見ると、虚血性心疾患を合併した心房細動でも3年の観察期間で起きるイベントはせいぜい15%程度です。 医療は本当に進歩しています。 https://t.co/4i5CA35hZA
RT @Bibleblack3: @May_Roma 例えば最近の文献で見ると、虚血性心疾患を合併した心房細動でも3年の観察期間で起きるイベントはせいぜい15%程度です。 医療は本当に進歩しています。 https://t.co/4i5CA35hZA
RT @Bibleblack3: @May_Roma 例えば最近の文献で見ると、虚血性心疾患を合併した心房細動でも3年の観察期間で起きるイベントはせいぜい15%程度です。 医療は本当に進歩しています。 https://t.co/4i5CA35hZA
RT @Bibleblack3: @May_Roma 例えば最近の文献で見ると、虚血性心疾患を合併した心房細動でも3年の観察期間で起きるイベントはせいぜい15%程度です。 医療は本当に進歩しています。 https://t.co/4i5CA35hZA
@May_Roma 例えば最近の文献で見ると、虚血性心疾患を合併した心房細動でも3年の観察期間で起きるイベントはせいぜい15%程度です。 医療は本当に進歩しています。 https://t.co/4i5CA35hZA
How about doac ?? Afire trial took patients with stable cad and afib and showed the rivaroxiban monotherapy was equally effective and safer compared to anti platelet + rivaroxiban!! https://t.co/SQkWH6yzu9
https://t.co/mekhpQJqMU
【S54-1】PCIまたはCABGを受けた心房細動患者でのリバーロキサバン単剤は抗血小板薬との併用と比較して、有効性は非劣性で、安全性は優れていた。https://t.co/7Rsg7CdYQN #jsphcs2021
@SripalBangalore @rwyeh https://t.co/foV6u7jT5u
RT @HadyLichaaMD: @BaylorCardio #AFIRE trial: https://t.co/ZqsYpUIvSQ Summary of recent #ACCExpertConsensus below #AtrialFibrillation #St…
@BaylorCardio #AFIRE trial: https://t.co/ZqsYpUIvSQ Summary of recent #ACCExpertConsensus below #AtrialFibrillation #StableCAD #Cardiotwitter #EPeeps @kerrigjl @cardiofrizz @melchami99 @DrAnkitKPatel @AnkurKalraMD @BagaiJayant @mobitz @evhaddad @Amyers235 @TTelila @KevinShahMD https://t.co/a1PtBRMQrE
@adityasharmamd @heatherlgornik @GBarnesMD @EstherSHKimMD @2Scottish @YogenKanthi @SVM_tweets @DKadiandodov Cardiology fellow informed me of AFIRE trial. https://t.co/FhTqWwnmzV For stable CAD, riva noninferior to riva + aspirin for efficacy, superior for safety. Anticoagulation alone is OK!
@drjohnm @JAMAInternalMed @GBarnesMD Arguably this was shown to be the case in AFIRE. Where the randomisation limited the biases and allowed a determination of treatment effect. https://t.co/YQy5sOUtoZ
RT @DrDerekConnolly: The Afire study of 2236 AF patients >1 yr post PCI/CABG/angioCAD NOAC was non-inferior to combo NOAC/anti-platelet t…
RT @DrDerekConnolly: The Afire study of 2236 AF patients >1 yr post PCI/CABG/angioCAD NOAC was non-inferior to combo NOAC/anti-platelet t…
RT @DrDerekConnolly: The Afire study of 2236 AF patients >1 yr post PCI/CABG/angioCAD NOAC was non-inferior to combo NOAC/anti-platelet t…
RT @DrDerekConnolly: The Afire study of 2236 AF patients >1 yr post PCI/CABG/angioCAD NOAC was non-inferior to combo NOAC/anti-platelet t…
The Afire study of 2236 AF patients >1 yr post PCI/CABG/angioCAD NOAC was non-inferior to combo NOAC/anti-platelet therapy for efficacy but SUPERIOR for bleeding DOI: 10.1056/NEJMoa1904143 this sub-analysis shows this is irrespective of the risks of stroke/bleeding @PCCS_UK https://t.co/UzRK6ipXD5
RT @aayshacader: #ESCardioAsia Dr Yasuda recaps #AFIRE trial Rivaroxaban monotherapy non-inferior to combination therapy for efficacy & su…
RT @aayshacader: #ESCardioAsia Dr Yasuda recaps #AFIRE trial Rivaroxaban monotherapy non-inferior to combination therapy for efficacy & su…
RT @aayshacader: #ESCardioAsia Dr Yasuda recaps #AFIRE trial Rivaroxaban monotherapy non-inferior to combination therapy for efficacy & su…
RT @aayshacader: #ESCardioAsia Dr Yasuda recaps #AFIRE trial Rivaroxaban monotherapy non-inferior to combination therapy for efficacy & su…
#ESCardioAsia Dr Yasuda recaps #AFIRE trial Rivaroxaban monotherapy non-inferior to combination therapy for efficacy & superior for safety in AF pts w stable CAD
Roshni Shibad: Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103-1113. Mentor: Craig Williams 3/ https://t.co/apfAI26aKi
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease July 23, 12:00 PM https://t.co/26yRWRsWbw https://t.co/t4Y86jDPhO
RT @thrombosisday: WEBINAR ANNOUNCEMENT! Join the @AnticoagForum this THURSDAY for a webinar on Antithrombotic Therapy for Atrial Fibrillat…
RT @thrombosisday: WEBINAR ANNOUNCEMENT! Join the @AnticoagForum this THURSDAY for a webinar on Antithrombotic Therapy for Atrial Fibrillat…
WEBINAR ANNOUNCEMENT! Join the @AnticoagForum this THURSDAY for a webinar on Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease at 12:00 p.m. (ET-US). To register, please visit: https://t.co/92DjSQwSmQ #WTDay20 https://t.co/WeQuBFlH45
Good time to review the #AFIRE trial: Showed rivaroxaban monotherapy was noninferior to combo Rx (with ASA) for efficacy and superior for safety in patients with atrial fibrillation and stable CAD (> 1 year out from PCI). ~30% with prior MI. https://t.co/7ulPMdYTlk
RT @thrombosisday: WTD PARTNER WEBINAR ANNOUNCEMENT: Join @AnticoagForum for a webinar on Antithrombotic Therapy for Atrial Fibrillation wi…
RT @thrombosisday: WTD PARTNER WEBINAR ANNOUNCEMENT: Join @AnticoagForum for a webinar on Antithrombotic Therapy for Atrial Fibrillation wi…
RT @thrombosisday: WTD PARTNER WEBINAR ANNOUNCEMENT: Join @AnticoagForum for a webinar on Antithrombotic Therapy for Atrial Fibrillation wi…
WTD PARTNER WEBINAR ANNOUNCEMENT: Join @AnticoagForum for a webinar on Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease on Thursday, 7/23/20 at 12:00 p.m. (ET-US). To register, visit: https://t.co/92DjSQwSmQ #WTDay20 https://t.co/Ghe93QO7ab
RT @Clotmaster: If you add aspirin to a DOAC you will cause way more bleeding so you better make sure it's worth it (it probably is not wor…
AFIRE trial (2019) 2236 pts w/ Afib and stable CAD as defined above randomized to rivaroxaban vs rivaroxaban+antiplatelet. Primary outcome - all cause mortality, MI, stroke, unstable angina requiring revasc, or systemic emb https://t.co/KXcntliiIj
Terapia antitrombótica para la #fibrilación auricular con enfermedad coronaria estable vía @NEJM [EN] https://t.co/Y1BHe0G3d2
@ChrisZhouDO I think this is a good start but note that patients who have CAD and afib _DON'T_ need to be treated with both antiplatelet and anticoagulant therapy --> increased risks with no clear benefit: https://t.co/mlS48ezhMJ
アスピリン+DOACからDOAC単剤への切り替えを後押ししてくれるすんばらしい試験。今日も迷える専攻医の先生と共有。 #CAD #心房細動 #AFIRE https://t.co/ycPaeHcwaj
AFIRE Trial Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/GENklzlC0o https://t.co/jT3vqR4uzc
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/vwettibSUA
@FZores ... pour rebondir, même en attendant AQUATIC, on a déjà des éléments de réponse assez fort avec AFIRE je trouve : Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/R5h4DRPHEh https://t.co/9JqAuqpTKQ
RT @vass_vassiliou: What do you do in pts with a stent >12 months & #AF? Antiplatelet & anticoagulant? This Japanese study @NEJM suggests t…
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/O0Du2z9CpD
@PLooserMD https://t.co/cDsUhCtclc AFIRE trial would favor DOAC alone. But I would take anatomy into account as well (small stents? bifurcation stents?). In young patients like this our EP typically drop DOAC after a period of monitoring so then would resume antiplatelet after that
RT @CianPMcCarthy: Will the AFIRE trial change your management of patients with stable CAD requiring concomitant anticoagulation? https://…
@NickCurzen @DocSavageTJU @mmamas1973 @CMichaelGibson @Drroxmehran @rwyeh @SVRaoMD @DLBHATTMD @GreggWStone @DrMarthaGulati @ajaykirtane @mirvatalasnag @djc795 @fischman_david is this not enough Nick?; https://t.co/kaxert6yZJ
RT @Manugrillo2: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/oPTRtyp7Ie #Rivaroxaban ht…
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/oPTRtyp7Ie #Rivaroxaban https://t.co/oWAiPNsZKm
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/13rZfN85NX
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/QdSTjoBFjz
AFIRE study gives us more confidence to use a DOAC alone in stable coronary artery disease patients (at least 12 months after PCI). Thank @GBarnesMD for the great talk @ThrombosisCan #knowthrombosis https://t.co/cmKEVapBAj
RT @Manugrillo2: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/ArZtLAJZCQ #Rivaroxaban #A…
https://t.co/unNkiz2xpI
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. - PubMed - NCBI https://t.co/h4CNTU4uej
RT @Manugrillo2: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/ArZtLAJZCQ #Rivaroxaban #A…
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/ArZtLAJZCQ #Rivaroxaban #AFib
#OTILT New trial from Japan (N Engl J Med 2019) showed rivaroxaban monotherapy was noninferior to combo therapy with antiplatelets for primary efficacy endpoints and SUPERIOR in terms of safety aka major bleeding in #Afib and #CAD patients. #TwitteRx https://t.co/oT1sZ7ItUN
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. https://t.co/4gxBYhvbU5
RT @NEJM: Patients with atrial fibrillation and stable coronary artery disease were assigned to receive either rivaroxaban monotherapy or c…
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
What's the best antithrombotic strategy for patients with AF and stable CAD? Via @NEJM https://t.co/7HMZ2helb4
#EBM EvidenceAlerts | Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. https://t.co/uJkOLRD23Q
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/IJYe3J76BM
RT @vass_vassiliou: What do you do in pts with a stent >12 months & #AF? Antiplatelet & anticoagulant? This Japanese study @NEJM suggests t…
RT @wakehealthHM: Tareq Islam, our #hospitalist #research expert leading our monthly #JournalClub today at #WakeHospitalMedicine on "Antith…
A new study is out in the New England Journal of Medicine called "Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease." You can request this article through your library resources. https://t.co/9m1oaVs4Pi
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Patients with atrial fibrillation and stable coronary artery disease were assigned to receive either rivaroxaban monotherapy or c…
I think these findings are very interesting given the prevalence of #Afib in our patient population. Is it much of a stretch to consider these results in patients with stable #PAD more than 1 year after treatment? Thoughts? @jmills1955 @NealBarshes https://t.co/HELGkxRd8m
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @Clotmaster: If you add aspirin to a DOAC you will cause way more bleeding so you better make sure it's worth it (it probably is not wor…
En este caso menos es más #cardiacsurgery #prevention #atrialfibrillation Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/h76iACk5gz
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
Antithrombotic Therapy for Atrial Fibrillation With Stable Coronary Disease https://t.co/ZxpOgAdyHB via @practiceupdate
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
RT @NEJM: Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
Original Article: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/KbxFuhbUAG
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/XI5woMzwAq
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
Tareq Islam, our #hospitalist #research expert leading our monthly #JournalClub today at #WakeHospitalMedicine on "Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease." What a fantastic discussion and a great way to end the week! https://t.co/ilz1RfLmn6
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
RT @DanielReyAldana: Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Ant…
Rivaroxaban en monoterapia frente Rivaroxaban+Antiagregante en #pacientes con #FA y cardiopatia isquemica estable. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/A008Lu6LAU https://t.co/RlixMkw8Jh
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM "The trial was stopped early because of increased mortality in the combination-therapy group"... https://t.co/WQ9g8GwgQl https://t.co/lqppPYUVgc
RT @Manugrillo2: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM #AFib #CAD #Rivaroxaban https://t.co/Y…
RT @GRIMEX_: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/PS3TfhshgP
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/t6e45eb52k
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/PS3TfhshgP
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/qxRiLqgy3G
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/QdPC4UV4ow
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/sj1O8BlvX5
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM #AFib #CAD #Rivaroxaban https://t.co/YT36yJcA55
Practice changing? Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/fpFs0For7S
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | via @NEJM. Spoiler...DOAC is just fine, don't need the antiplatelet agent if stable CAD. https://t.co/AwLS8xKaqP
RT @kojima_aponet: 【N Engl J Med】 Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. https://t.co/cTb2OlIRYp
RT @kojima_aponet: 【N Engl J Med】 Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. https://t.co/cTb2OlIRYp
RT @kojima_aponet: 【N Engl J Med】 Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. https://t.co/cTb2OlIRYp
RT @kojima_aponet: 【N Engl J Med】 Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. https://t.co/cTb2OlIRYp
RT @kojima_aponet: 【N Engl J Med】 Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. https://t.co/cTb2OlIRYp
【N Engl J Med】 Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. https://t.co/cTb2OlIRYp
RT @joscarlor2: As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for saf…
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/vtk2Pf57Gf
RT @joscarlor2: As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for saf…
RT @joscarlor2: As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for saf…
RT @joscarlor2: As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for saf…
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM #NOACs alone is effictive and safer than triple therapy PS -stable coronary disease has new name; "chronic coronary syndrome" #CCS ✔️ https://t.co/CwEQFQJcyo https://t.co/ASK2gbHEJi
RT @joscarlor2: As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for saf…
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease | NEJM https://t.co/8ZaLUwp489
RT @joscarlor2: As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for saf…
Interesting to read from @NEJM Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease https://t.co/PTxgcY2SiE
DOI: 10.1056/ 2013, 76(1):89‑98. DOI: 10.1111/bcp.12054. NEJMoa1904143. [124] Lee HF, Chan YH, Chang SH, et al. Effectiveness and safety [112] Banerjee A ...
tervention in atrial fibrillation patients with or without acute coronary 10.1056/NEJMoa0706482 ... doi: 10.1056/NEJMoa1904143. 596 February 9, 2021 Circulation.
org/doi/full/10.1056/NEJMoa1904143?url_ver=Z39.8 8-2003&rfr_id=ori:rid:crossref. org&rfr_dat=cr_pub%3dpubmed · Guenaelle Hinault and 5 others ·
DOI: 10.1056/NEJMoa1904143 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct ...
https://doi.org/10.1056/NEJMoa1611594 synthesis practice for meta-analysis with zero- 1113. https://doi.org/10.1056/NEJMoa1904143 events studies. J Clin ...
https://doi.org/10.1056/NEJMoa1904143 ESC guidelines on cardiovascular disease preven- circulatory support: executive summary. J Heart tion in clinical ...
doi:10.1056/NEJMoa1904143 EAST-AFNET 4 trial. Eur Heart J. 2022;43(12):1219- paroxysmal atrial fibrillation. N Engl J Med. 2012; 67. Lip GY, Frison L ...
doi:10.1056/NEJMOA1904143/SUPPL_FILE/NEJMOA1904143_DATA-SHARING.PDF 105. Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with ...
doi:10.1056/NEJMoa1904143 . Newsletter. Join thousands of clinicians staying current on new therapies, trial data, and expert insights ...
This trial showed DOAC alone to decrease bleeding WITHOUT a change in ischemic events when compared to DOAC + antiplatelet.
https://doi.org/10.1056/NEJMoa1904143. 325. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. Open-label ...
... 10.1056/NEJMoa1904143). Differenziert zu betrachten sind hingegen Patienten mit Vorhofflimmern und einem akuten oder chronischen ...
... 10.1056/NEJMoa1904143). Differenziert zu betrachten sind hingegen Patienten mit Vorhofflimmern und einem akuten oder chronischen ...
2019; doi: 10.1056/NEJMoa1904143. Leggi. 119. SCOMPENSO. CARDIACO. LINEE GUIDA. DISLIPIDEMIE. VARIE. CORONAROPATIA. ARITMOLOGIA. Page 120. È ...
... 10.1056/NEJMoa1908077?query=featured_home Angiotensin–Neprilysin ... org/doi/full/10.1056/NEJMoa1904143?query=feature d_home ที่เหลือจะ ...
... 10.1056/NEJMoa1908077?query=featured_home Angiotensin–Neprilysin ... org/doi/full/10.1056/NEJMoa1904143?query=feature d_home ที่เหลือจะ ...
2019;doi:10.1056/NEJMoa1904143. Disclosures: Yasuda reports he receives research contracts from Takeda, financial ties with Abbott, and ...
N
末臨
HR
PC
DM
DA
お
TH
R
田仕
TN
東循
色ガ
SY
S佐
M
まP
Tね
RF
CM
SH
AM
C
SM
WM
L
BM
イ
PM
KF
TF
黒猫
M
七
A
Mめ
BB
SM
し昇
P
OB
AS
JA
DM
TD
A
JO
LM
LT
DF
RM
AC
AP
DG
JH
DH
DA
S
WD
HM
AB
CO
RL
O
OM
LM
JM
官H
KC
US
MK
EM
HB
MS
AJ
MS
AM
AC
CC
AB
AG
HP
に
AS
E
E
ĐH
阿P
AC
CH
L
AS
MG
JB
GA
TT
FE
ΠΑ
洪
CC
S
LB
CA
KV
T
A
LR
MM
AA
P
N
DH
A
C
DM
DM
YM
PM
AS
JU
HB
RC
BD
SA
PV
SG
PK
MS
RM
GE
DV
TU
Mل
AM
AP
K
TP
N
E
青発
小P
SA
RV
F
DE